306
viding significant information for the establishment of
ADME profile of the studied drug.
(b) In the second presented example, Pippa et al. [12] developed thermoresponsive chimeric liposomes by incorporating the two different forms of the thermoresponsive
amphiphilic homopolymer and more specifically C 12 H 25 -
poly(N- isopropylacrylamide)-COOH (C 12 H 25 -PNIPAMCOOH) into DPPC liposomes, while the hydrophobic
drug indomethacin was also incorporated.
Fig. 2 DSC scans of (a) pure DPPC bilayers; (b) DPPC/irbesartan bilayers (80:20);
(c) DPPC/HP-β-CD bilayers (80:20); (d) DPPC MLV dispersion with [irbesartan/
HP-β-CD] added (80:20); and (e) DPPC/[irbesartan/HP-β-CD] bilayers (80:20).
Adapted from Ref. [17]
Table 1
Thermal parameters for different DPPC samples studied
Samples
Pre-transition state
Transition state
ΔΗ (J/g) T pre (°C) ΔΗ (J/g)
T m
(°C)
DPPC
6.3
35
41.8
41.2
DPPC/IRB (80:20)
–
–
40.8
39.7
DPPC/HP-β-CD (80:20) 3.9
33
34.0
39.3
DPPC/[IRB–HP-β-CD]
complex added (80:20)
–
–
38.2
39.3
DPPC/[IRB–HP-β-CD]
(80:20)
–
–
41.0
39.8
Adapted from Ref. [17]
Maria Chountoulesi et al.
viding significant information for the establishment of
ADME profile of the studied drug.
(b) In the second presented example, Pippa et al. [12] developed thermoresponsive chimeric liposomes by incorporating the two different forms of the thermoresponsive
amphiphilic homopolymer and more specifically C 12 H 25 -
poly(N- isopropylacrylamide)-COOH (C 12 H 25 -PNIPAMCOOH) into DPPC liposomes, while the hydrophobic
drug indomethacin was also incorporated.
Fig. 2 DSC scans of (a) pure DPPC bilayers; (b) DPPC/irbesartan bilayers (80:20);
(c) DPPC/HP-β-CD bilayers (80:20); (d) DPPC MLV dispersion with [irbesartan/
HP-β-CD] added (80:20); and (e) DPPC/[irbesartan/HP-β-CD] bilayers (80:20).
Adapted from Ref. [17]
Table 1
Thermal parameters for different DPPC samples studied
Samples
Pre-transition state
Transition state
ΔΗ (J/g) T pre (°C) ΔΗ (J/g)
T m
(°C)
DPPC
6.3
35
41.8
41.2
DPPC/IRB (80:20)
–
–
40.8
39.7
DPPC/HP-β-CD (80:20) 3.9
33
34.0
39.3
DPPC/[IRB–HP-β-CD]
complex added (80:20)
–
–
38.2
39.3
DPPC/[IRB–HP-β-CD]
(80:20)
–
–
41.0
39.8
Adapted from Ref. [17]
Maria Chountoulesi et al.
